Navigating the Complexities of HIV/AIDS Clinical Trials:

Diagnosis, Endpoints, and Regulatory Pathways

INGENŪ CRO

Introduction

HIV (Human Immunodeficiency Virus) is a virus that specifically attacks the body's immune system, focusing on CD4 cells, which are essential in fighting infections.

Without treatment, HIV progressively weakens the immune system, leading to AIDS (Acquired Immunodeficiency Syndrome), an advanced stage characterized by life-threatening infections and cancers. HIV/AIDS remains a major global health issue, significantly impacting health systems, economies, and the quality of life of affected individuals.

While there is no cure for HIV, advancements in antiretroviral therapy (ART) have enabled many to live longer, healthier lives while reducing the risk of virus transmission. This whitepaper explores the landscape of HIV/AIDS clinical trials, covering diagnostic criteria, epidemiology, and pivotal endpoints critical to evaluating treatment efficacy. It also delves into challenges in endpoint determination, reviews FDA-approved drugs and failed drug candidates, identifies common failure points in clinical trials, and discusses safety concerns. Finally, it offers strategies to enhance clinical trial protocols, driving progress in the fight against HIV/AIDS.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Insights in HIV/AIDS

Key Characteristics

HIV/AIDS progresses through several stages, beginning with acute HIV infection, followed by a chronic stage, and finally, if untreated, AIDS. Early symptoms often resemble flu-like illness, but as the virus multiplies and destroys immune cells, the immune system becomes more vulnerable. AIDS is characterized by a dangerously low CD4 count (below 200 cells/mm^3) or the presence of opportunistic infections and certain cancers. Treatment with ART can slow this progression, and when effectively managed, the virus can be suppressed to undetectable levels, reducing transmission risk and preventing the onset of AIDS.

Factors Contributing to HIV/AIDS:

- **Biological Factors:** HIV is primarily spread through specific biological mechanisms that include unprotected sexual contact, sharing of needles, or transmission from mother to child during childbirth or breastfeeding. Viral load (the amount of virus in the bloodstream) is a critical factor; higher viral loads significantly increase transmission risk. Coinfection with other sexually transmitted infections (STIs) can also exacerbate HIV transmission, as STIs cause inflammation that provides easier access for the virus to enter the bloodstream.
- **Psychological Factors:** Psychological and social factors, such as stigma and mental health challenges, often lead to delays in HIV testing, diagnosis, and treatment initiation. Stigma associated with HIV/AIDS can lead to isolation and reduced healthcare engagement, ultimately hindering effective treatment. Mental health conditions, including depression and anxiety, are common among people with HIV, potentially leading to poor adherence to treatment regimens, which is essential for viral suppression.
- **Environmental Factors:** Access to healthcare resources and social determinants like poverty, housing instability, and limited education play significant roles in HIV risk and management. Populations in low-resource settings or those with limited access to preventive measures, such as condoms and clean needles, face higher risks of HIV transmission. Social factors, including migration and urbanization, also contribute to disease spread by increasing the likelihood of high-risk behaviors, particularly in densely populated or underserved regions.

Trends and Market

Prevalence and Trend Analysis

Globally, HIV/AIDS prevalence has shown a declining trend in incidence rates due to prevention and treatment efforts, particularly in high-income countries with advanced healthcare systems. However, certain regions, such as sub-Saharan Africa, continue to have high prevalence rates due to economic and healthcare challenges. As of 2021, an estimated 38.4 million people were living with HIV worldwide. Projections for the next decade anticipate further reductions in new infections in well-resourced areas, but socioeconomic disparities may continue to sustain higher prevalence in underserved populations.

Market Overview for HIV/AIDS Treatment

The market for HIV/AIDS treatment is substantial and expanding, driven by the demand for ongoing ART, preventive therapies like PrEP, and novel drug developments. The market for HIV therapeutics was valued at approximately USD 30 billion in 2022 and is projected to grow due to advances in treatment options, the push for universal healthcare coverage, and the development of long-acting formulations and vaccines. Factors influencing this growth include increased access to HIV care in low-income countries and ongoing innovation in drug formulations.

Drug Name	Manufacturer	Market Share (%)	Earning Potential (USD million)
Biktarvy	Gilead Sciences	29%	7,700
Genvoya	Gilead Sciences	12%	3,200
Triumeq	GlaxoSmithKline	11%	2,900
Descovy	Gilead Sciences	10%	2,500
Tivicay	GlaxoSmithKline	8%	1,900

ICD-11 Code and Diagnostic Criteria

ICD-11 Code for HIV Disease: 1C62

1. HIV-Specific Serological Testing: Initial screening is commonly performed using serological tests that detect antibodies to HIV in the blood. Enzyme-linked immunosorbent assay (ELISA) is typically the first step. A positive ELISA result is usually confirmed with a secondary test, like a Western Blot or immunofluorescence assay, which provides high specificity by identifying HIV proteins.

2. Viral Antigen Testing and NAT: To detect HIV infection at earlier stages or confirm cases with ambiguous serological results, viral antigen tests (such as p24 antigen tests) or nucleic acid tests (NAT) are used. These tests detect HIV RNA or DNA directly, providing a high sensitivity for recent infections and confirming the presence of the virus, even in cases where antibodies may not yet be detectable.

3. CD4 Cell Count Monitoring: The progression from HIV to AIDS is largely assessed by the count of CD4 T-cells in the bloodstream. AIDS is diagnosed when the CD4 count falls below 200 cells/mm³ or when specific AIDS-defining illnesses (such as certain opportunistic infections or cancers) develop. CD4 counts also serve as a measure of immune system health and are monitored regularly in HIV-positive individuals to track disease progression.

4. Opportunistic Infections and AIDS-Defining Conditions: AIDS is defined by either a critically low CD4 count or the occurrence of opportunistic infections or cancers associated with severe immunodeficiency. Examples include Pneumocystis pneumonia, Kaposi's sarcoma, and invasive cervical cancer, all of which are indicators of advanced immunosuppression and thus a criterion for an AIDS diagnosis.

5. Rapid Testing and Point-of-Care Tests: In many settings, particularly low-resource areas, rapid diagnostic tests (RDTs) are utilized. These tests can quickly provide preliminary HIV status through a fingerstick blood sample or oral fluid, though confirmatory testing is recommended for a positive RDT result.

Evolution of Diagnostic Criteria Over Time

Early diagnostic methods relied on symptom identification and rudimentary antibody testing, which often failed to detect the virus in early stages. The development of ELISA and Western Blot tests marked significant progress in the 1980s. In subsequent decades, molecular tests like NAT became available, allowing for earlier and more accurate diagnosis. Advances in diagnostic technology have improved early detection, disease management, and enabled a better understanding of HIV progression, supporting timely treatment initiation and the monitoring of treatment efficacy.

Impact of Diagnostic Advances on Clinical and Research Perspectives

Advancements in HIV diagnostics have been instrumental in transforming HIV from a fatal disease into a manageable chronic condition. Early and accurate detection has enhanced the ability to initiate ART sooner, improving patient outcomes and reducing transmission rates. For researchers, reliable diagnostics have facilitated cohort studies on disease progression, vaccine trials, and the development of novel therapies. The ICD-11 updates reflect this evolution, with classification codes and diagnostic descriptions that accommodate both high-sensitivity tests and rapid diagnostics, allowing for greater inclusivity and specificity in epidemiological research and global health reporting.

Epidemiology of HIV/AIDS

Global Prevalence

As of 2021, approximately 38.4 million people worldwide are living with HIV, making it one of the most pervasive infectious diseases globally. While new infections have declined due to increased access to antiretroviral therapies and prevention efforts, certain regions, especially sub-Saharan Africa, continue to bear the highest burden. The global response to HIV aims to reduce prevalence further, but socioeconomic and healthcare access disparities present ongoing challenges in reaching these goals universally.

1. Prevalence by Age

HIV prevalence varies significantly by age, with the highest rates seen in adults aged 15–49, who are often in high-risk demographics. Adolescents and young adults (ages 15-24) represent a significant portion of new cases, driven by factors like limited access to sexual health education and prevention services. Older adults (over 50) living with HIV are also increasing in number, largely due to effective treatment that extends lifespan, although this population faces unique health challenges related to aging and HIV.

2. Prevalence by Gender

Globally, HIV prevalence affects men and women differently, with gender dynamics influencing transmission rates. In sub-Saharan Africa, women account for nearly 60% of HIV cases due to factors like gender inequality, economic dependency, and limited access to preventive resources. In other regions, particularly in North America and Europe, men who have sex with men (MSM) represent a higher proportion of HIV cases, underscoring how gender and sexual orientation affect vulnerability to the disease.

3. Prevalence by Race and Ethnicity

In the United States, African American and Hispanic populations have a disproportionately higher prevalence of HIV compared to other racial and ethnic groups, with African Americans accounting for over 40% of all new cases despite being a smaller percentage of the total population. This disparity is largely driven by socioeconomic factors, healthcare access barriers, and systemic

INGENŪ CRO

Key Endpoints for FDA Approval of HIV Drugs

1. Viral Load Suppression:

Overview: Sustained reduction in plasma HIV RNA levels to undetectable levels is a primary efficacy endpoint. The FDA generally requires data showing that the new drug can achieve viral suppression by the 24-week mark and sustain it through the 48-week endpoint, as this duration demonstrates both initial efficacy and longer-term control.

Recommendation: Ensure rigorous viral load testing at multiple intervals (e.g., weeks 4, 12, 24, 48) to provide detailed data on time to viral suppression and the durability of effects, which can enhance confidence in the drug's performance over time.

2. Inclusion of Long-Acting Formulations:

Overview: Long-acting injectables are becoming a preferred alternative for patients who struggle with daily dosing. Including both oral and long-acting injectable forms in a single protocol can demonstrate the drug's versatility and address a broader range of patient needs.

Benefit: This approach aligns with the FDA's emphasis on practical, patient-centered treatments and could improve the drug's market appeal if approved, as it meets various adherence and lifestyle requirements.

3. Real-World Evidence (RWE) Collection:

Overview: Collecting real-world evidence (e.g., data from observational studies or patient registries) can supplement clinical trial data, particularly for safety, tolerability, and adherence in diverse populations.

Benefit: The FDA increasingly values RWE, especially for chronic conditions like HIV, as it provides additional insights into how the drug performs outside of the clinical trial setting. Including a real-world evidence component strengthens the application and could facilitate expanded approval.

4. Diverse Participant Recruitment:

Overview: Ensuring diversity in trial participants by including individuals from different racial, ethnic, gender, and age groups improves the generalizability of the findings. HIV disproportionately affects certain demographics, so data on how different populations respond to the drug is important for both the FDA and for meeting public health needs.

Benefit: Trials with diverse populations allow the FDA to assess drug safety and efficacy across varied demographics, potentially easing the path to broader approval and addressing disparities in HIV treatment.

5. Patient-Reported Outcome Measures:

Overview: Including PROMs, such as surveys on quality of life, symptom burden, and treatment satisfaction, adds a patient-centric perspective to the data. This can be especially valuable in HIV, where long-term treatment adherence is closely tied to patient experience.

Benefit: The FDA has a strong interest in patient-focused drug development, and positive PROM data may support claims of improved adherence, tolerability, and quality of life, which can differentiate the drug in the approval process.

Five Most Commonly Prescribed Drugs for HIV/AIDS

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Biktarvy	2018	Gilead Sciences	Biktarvy combines three drugs: bictegravir (an integrase inhibitor) and two NRTIs (emtricitabine and tenofovir alafenamide). Bictegravir blocks the integrase enzyme, preventing viral DNA from integrating into the host genome, which halts viral replication. The NRTIs interfere with viral RNA replication by causing premature chain termination.	Biktarvy effectively suppresses viral load in HIV-positive patients, leading to undetectable viral levels in the blood when taken consistently. It helps increase CD4 cell counts, restoring immune function, and provides a once-daily treatment option that simplifies adherence.
Truvada	2004	Gilead Sciences	Truvada contains two nucleoside reverse transcriptase inhibitors (NRTIs): tenofovir disoproxil fumarate and emtricitabine. These NRTIs interfere with the reverse transcriptase enzyme, essential for converting viral RNA into DNA, effectively blocking viral replication.	Used both for treatment and as pre-exposure prophylaxis (PrEP), Truvada is highly effective in reducing viral load in HIV-positive individuals and preventing infection in HIV-negative individuals when taken consistently, significantly reducing transmission rates.
Atripla	2006	Gilead Sciences	Atripla combines efavirenz (a non-nucleoside reverse transcriptase inhibitor, or NNRTI) with two NRTIs (tenofovir and emtricitabine). Efavirenz binds to reverse transcriptase, directly blocking its function, while the NRTIs cause premature termination of viral DNA synthesis.	Atripla reduces viral load by effectively blocking HIV replication at multiple stages, leading to decreased viral presence and increased CD4 counts. As a single-pill regimen, it improves adherence, although some users report neuropsychiatric side effects from efavirenz.
Dovato	2019	GlaxoSmithKline	Dovato includes dolutegravir (an integrase inhibitor) and lamivudine (an NRTI). Dolutegravir blocks HIV integrase, preventing integration of viral DNA into host cells, while lamivudine incorporates into viral DNA and halts its synthesis.	Dovato offers a two-drug regimen that provides effective viral suppression with a lower drug burden than traditional three-drug regimens, thus reducing potential side effects. It helps patients maintain undetectable viral levels with once-daily dosing.
Triumeq	2014	GlaxoSmithKline	Triumeq combines dolutegravir (an integrase inhibitor) with two NRTIs (abacavir and lamivudine). Dolutegravir prevents HIV DNA from integrating into host DNA, while the NRTIs disrupt viral DNA synthesis by incorporating faulty building blocks into viral DNA.	Triumeq reduces HIV replication, leading to undetectable viral loads in treated patients and an increase in CD4 counts. It is a once-daily treatment that improves adherence, though patients with specific genetic markers must be screened for abacavir hypersensitivity.

Pivotal Clinical Trials Leading to FDA Approval

Drug Name	Study Name/Clinical Trial Identifier	Sample Size	Key Findings & Statistical Data
Biktarvy	NCT02607930	600	Biktarvy was shown to be highly effective, achieving viral suppression in 98% of participants at 48 weeks, with a statistically significant improvement in CD4 counts ($p < 0.001$). This study demonstrated non-inferiority compared to standard-of-care regimens and highlighted Biktarvy's safety profile with minimal side effects.
Truvada	NCT00105154	1,800	In this study, Truvada as PrEP (pre-exposure prophylaxis) reduced the risk of HIV infection by over 90% among high-risk, HIV-negative individuals when taken daily, confirming its efficacy for prevention. Participants who adhered consistently to the regimen showed the highest levels of protection, underscoring the importance of adherence in PrEP effectiveness.
Atripla	NCT00256828	1,000	Atripla achieved sustained viral suppression in 86% of treatment-naïve patients at 96 weeks, showing significant improvement in CD4 counts. Despite its effectiveness, a notable percentage of participants reported neuropsychiatric side effects, including vivid dreams and dizziness, associated with efavirenz.
Dovato	NCT02505873	720	Dovato was shown to be non-inferior to three-drug regimens, with 90% of participants achieving undetectable viral loads at 48 weeks and showing significant CD4 cell recovery. The study confirmed that a two-drug regimen could be effective and well-tolerated, offering a simplified treatment option with fewer long-term toxicities.
Triumeq	NCT01864823	800	Triumeq demonstrated a high rate of viral suppression, with 89% of participants maintaining undetectable viral loads after 48 weeks of treatment, alongside substantial CD4 count increases. The study noted that patients must undergo HLA-B*5701 screening to reduce the risk of abacavir hypersensitivity, which is critical for patient safety.

Approved Product Analysis: Biktarvy

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with no antiretroviral treatment history	HIV-1 RNA < 50 copies/mL	Not specified	144 weeks + 96 OLE	N=314 (BIKTARVY), N=315 (ABC/DTG/3TC)	BIKTARVY: 82%, Comparator: 84%; Treatment difference: -2.6% (-8.5% to 3.4%)
	HIV-1 RNA ≥ 50 copies/mL	Not specified	144 weeks + 96 OLE	N=320 (BIKTARVY), N=325 (DTG + FTC/TAF)	BIKTARVY: 82%, Comparator: 84%; Treatment difference: -1.9% (-7.8% to 3.9%)
Virologically-suppressed adults	Switch to BIKTARVY	Not specified	48 weeks	N=282 (BIKTARVY), N=281 (ABC/DTG/3TC)	HIV-1 RNA < 50 copies/mL: BIKTARVY: 94%, Comparator: 95%; Treatment difference: 0.7% (-1.0% to 2.8%)
Virologically-suppressed adults	Switch to BIKTARVY	Not specified	48 weeks	N=290 (BIKTARVY), N=287 (ATV or DRV-based regimen)	HIV-1 RNA < 50 copies/mL: BIKTARVY: 92%, Comparator: 89%; Treatment difference: 0.0% (-2.5% to 2.5%)
Virologically-suppressed adults with ESRD on hemodialysis	Efficacy and safety evaluation	Not specified	96 weeks (extension 48 weeks)	N=55 (FTC+TAF in combination with elvitegravir/cobicistat)	All subjects remained virologically suppressed (HIV-1 RNA < 50 copies/mL) at Week 48 extension.
Virologically-suppressed adults aged 65+	Switch to BIKTARVY	Not specified	48 weeks	N=86 (BIKTARVY)	91% of subjects remained virologically suppressed (HIV-1 RNA < 50 copies/mL) at Week 48.
Virologically-suppressed adolescents (12-18 years, ≥ 35 kg)	Switch to BIKTARVY	Not specified	48 weeks	N=50 (BIKTARVY)	98% (49/50) of subjects remained virologically suppressed (HIV-1 RNA < 50 copies/mL); CD4+ cell count change: -22 cells/mm³
Virologically-suppressed children (6-12 years, ≥ 25 kg)	Switch to BIKTARVY	Not specified	24 weeks	N=50 (BIKTARVY)	100% (50/50) of subjects remained virologically suppressed (HIV-1 RNA < 50 copies/mL); CD4+ cell count change: -24 cells/mm³
Virologically-suppressed children (2-6 years, 14-25 kg)	Switch to BIKTARVY	Not specified	24 weeks	N=22 (BIKTARVY)	91% (20/22) of subjects remained virologically suppressed (HIV-1 RNA < 50 copies/mL); CD4+ cell count change: -126 cells/mm³ (SD: 264.2)

Approved Product Analysis: TRUVADA

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Antiretroviral-naive adults (Study 934)	Comparison of FTC + TDF vs. AZT/3TC + EFV for HIV suppression	Not specified	48 weeks / 144 weeks	N=244 (FTC + TDF + EFV), N=243 (AZT/3TC + EFV)	Week 48: 84% responders (FTC + TDF), 73% responders (AZT/3TC); Week 144: 71% (FTC + TDF), 58% (AZT/3TC). Virologic failure: Week 48: 2% (FTC + TDF), 4% (AZT/3TC); Week 144: 3% (FTC + TDF), 6% (AZT/3TC). CD4+ increase at Week 48: 190 cells/mm³ (FTC + TDF), 158 cells/mm³ (AZT/3TC); Week 144: 312 cells/mm³ (FTC + TDF), 271 cells/mm³ (AZT/3TC).
HIV-seronegative men and transgender women at high risk for HIV (iPrEx Trial)	Incidence of HIV seroconversion	Not specified	End of treatment	N=1248 (Placebo), N=1251 (TRUVADA)	42% reduction in HIV risk with TRUVADA vs. placebo (95% CI: 18%-60%); 53% reduction among subjects with prior unprotected anal intercourse.
Heterosexual serodiscordant couples (Partners PrEP Trial)	HIV prevention efficacy in uninfected partners	Not specified	3 years	N=1583 (FTC/TDF), N=1586 (Placebo), N=1589 (TDF)	75% reduction in HIV risk with TRUVADA vs. placebo (95% CI: 55%-87%); efficacy strongly correlated with adherence.

Approved Product Analysis: ATRIPLA

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Antiretroviral-naive adults (Study 934)	Comparison of FTC + TDF + EFV vs. AZT/3TC + EFV for HIV suppression	Not specified	48 weeks / 144 weeks	N=244 (FTC + TDF + EFV), N=243 (AZT/3TC + EFV)	Week 48: 84% responders (FTC + TDF), 73% responders (AZT/3TC); Week 144: 71% (FTC + TDF), 58% (AZT/3TC). Virologic failure: Week 48: 2% (FTC + TDF), 4% (AZT/3TC); Week 144: 3% (FTC + TDF), 6% (AZT/3TC). CD4+ increase at Week 48: 190 cells/mm³ (FTC + TDF), 158 cells/mm³ (AZT/3TC); Week 144: 312 cells/mm³ (FTC + TDF), 271 cells/mm³ (AZT/3TC).
Subjects with stable, virologic suppression (Study 073)	Efficacy of switching to ATRIPLA from baseline regimen	Not specified	48 weeks	N=203 (ATRIPLA), N=97 (SBR - Standard Baseline Regimen)	89% (ATRIPLA) and 88% (SBR) maintained HIV RNA < 200 copies/mL; 87% (ATRIPLA) and 85% (SBR) maintained HIV RNA < 50 copies/mL. No significant difference in CD4+ cell counts between arms.

Approved Product Analysis: DOVATO

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
HIV-1–infected adults with no antiretroviral treatment history (GEMINI-1 and GEMINI-2)	Proportion of subjects with HIV-1 RNA <50 copies/mL	Snapshot Algorithm	48 weeks / 144 weeks	N=716 (TIVICAY + EPIVIR), N=717 (TIVICAY + TRUVADA)	Week 48: 91% (TIVICAY + EPIVIR) vs. 93% (TIVICAY + TRUVADA); Week 144: 82% vs. 84%. Adjusted differences: -1.7% (95% CI: -4.4%, 1.1%) at Week 48, -1.8% (95% CI: -5.8%, 2.1%) at Week 144.
	Virologic nonresponse				Virologic nonresponse at Week 48: 3% (TIVICAY + EPIVIR) vs. 2% (TIVICAY + TRUVADA); Week 144: 3% in both groups.
	CD4+ cell count change		144 weeks		Mean change in CD4+ count: 302 cells/mm³ (TIVICAY + EPIVIR), 300 cells/mm³ (TIVICAY + TRUVADA).
Virologically suppressed HIV-1–infected adults who switched to DOVATO (TANGO Trial)	Proportion of subjects with HIV-1 RNA <50 copies/mL	Snapshot Algorithm	96 weeks	N=369 (DOVATO), N=372 (TBR - Traditional Baseline Regimen)	86% in DOVATO group vs. 79% in TBR group. Adjusted treatment difference: 6.8% (95% CI: 1.4%, 12.3%).
	Virologic nonresponse				Virologic nonresponse: <1% in DOVATO group vs. 1% in TBR group at Week 96.
	CD4+ cell count change		96 weeks		Median change in CD4+ count from baseline: 61.0 cells/mm³ (DOVATO) vs. 45.0 cells/mm³ (TBR).

Approved Product Analysis: TRIUMEQ

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Treatment-naive adults (SINGLE trial)	Comparison of TIVICAY + EPZICOM vs. ATRIPLA for HIV suppression	Snapshot Algorithm	144 weeks	N=414 (TIVICAY + EPZICOM), N=419 (ATRIPLA)	Week 144: 71% responders (TIVICAY + EPZICOM) vs. 63% (ATRIPLA); Treatment difference: 8.3% (95% CI: 2.0%, 14.6%). Virologic nonresponse: 10% (TIVICAY + EPZICOM) vs. 7% (ATRIPLA).
					CD4+ increase: 378 cells/mm³ (TIVICAY + EPZICOM) vs. 332 cells/mm³ (ATRIPLA) at Week 144.
Treatment-experienced adults (SAILING trial)	Efficacy of TIVICAY plus background regimen vs. RAL plus background regimen for HIV suppression	Not specified	48 weeks	N=715 (total)	Week 48: 71% responders (TIVICAY) vs. 64% (RAL); Treatment difference: 7.4% (95% CI: 0.7%, 14.2%).
Pediatric subjects (IMPACT 2019 trial)	Efficacy of TRIUMEQ and TRIUMEQ PD in treatment-naive or treatment-experienced children <12 years	Snapshot Algorithm	48 weeks	N=57	79% achieved HIV-1 RNA <50 copies/mL; 95% achieved HIV-1 RNA <200 copies/mL.
Treatment-naive pediatric subjects (ARROW trial)	Efficacy of abacavir + lamivudine with third antiretroviral drug for HIV suppression	Not specified	96 weeks	N=336	67% of subjects achieved HIV-1 RNA <80 copies/mL at Week 96.
Pediatric subjects aged 4 weeks to 18 years (IMPAI ACT P1093)	Efficacy of dolutegravir (TIVICAY) + other ART drugs for HIV suppression	Snapshot Algorithm	48 weeks	N=36 (weighing at least 6 kg)	72% (26/36) of subjects achieved HIV-1 RNA <50 copies/mL at Week 48.

NGENŪ CRO

Analysis of Failed HIV/AIDS Drug Candidates

Name of Drug	NCT Number	Clinical Trial Identifier	Reason for Termination / Drug Failure
Fostemsavir	NCT01247282	Failed to demonstrate sufficient efficacy in multi-drug resistant HIV patients; high discontinuation due to side effects, including gastrointestinal and immune-related issues.	Single-mechanism drugs, like attachment inhibitors, often face efficacy challenges in patients with complex, drug-resistant HIV strains. Future trends indicate a shift toward combination therapies for these cases.
Islatravir	NCT03510457	Terminated due to immune-related adverse effects, notably significant reductions in lymphocyte counts, which raised concerns over immune suppression.	Recent failures of immune-modulating antiretrovirals underline the importance of safety and immune monitoring. Current trials are focused on lower dosing and combination strategies to enhance safety.
VRC01 (Antibody)	NCT02716675	Discontinued due to lack of efficacy in preventing HIV across diverse populations; the antibody failed to neutralize the full range of HIV strains.	Monoclonal antibodies are increasingly combined or paired with antiretrovirals to overcome limitations seen with single antibody approaches. Broadly neutralizing antibodies are being explored for improved efficacy.
AAV-Based Gene Therapy	NCT00858793	Terminated due to low gene expression and immune reactions against the viral vector, reducing therapeutic viability.	Gene therapies for HIV face significant challenges with vector immunogenicity and delivery efficiency. Research trends focus on optimizing viral vectors and combining gene therapy with ART for better outcomes.
HVTN 702 (Vaccine)	NCT02968849	Halted after failing to show efficacy in preventing HIV infection among high-risk populations in South Africa.	The development of HIV vaccines faces ongoing challenges due to HIV's high mutation rate. Recent trends in vaccine research are moving toward mRNA and mosaic vaccines to enhance immune response and broaden strain coverage.

Key Failure Points Encountered in HIV Clinical Trials

1. Patient Adherence and Retention

Case Example: In the HPTN 052 study, adherence issues affected the consistency of viral suppression in some participants, leading to periodic treatment failure.

Solution: To improve adherence, implement patient-centered interventions like mobile reminders, counseling, and simplified dosing regimens, such as once-daily single-pill options.

2. Drug Resistance Development

Case Example: In the DISCOVER trial, resistance mutations to tenofovir and emtricitabine were identified in cases of incomplete adherence, reducing drug efficacy.

Solution: Regular resistance testing and incorporating resistance education into patient counseling can help identify early resistance and encourage strict adherence.

3. Neuropsychiatric Side Effects

Case Example: Atripla (containing efavirenz) often causes neuropsychiatric effects, leading some participants to discontinue treatment due to vivid dreams and mood changes.

Solution: Screening for mental health history, offering alternative ART options without neuropsychiatric side effects, and providing mental health support can improve retention.

4. High Incidence of Adverse Events in Certain Populations

Case Example: The HVTN 505 vaccine trial failed due to adverse events and ineffectiveness, particularly among African American participants with specific immune responses.

Solution: Develop targeted recruitment strategies and genetic screening to identify populations with higher sensitivity, and tailor interventions to minimize adverse outcomes.

5. Lack of Efficacy in Diverse Populations

Case Example: The HVTN 702 vaccine trial in South Africa was halted due to a lack of efficacy in preventing HIV in local populations, despite success in other demographics.

Solution: Conduct early feasibility studies in diverse populations to assess efficacy and consider adaptive trial designs that allow for adjustments based on subgroup results.

6. Recruitment Challenges in At-Risk Groups

Case Example: Trials targeting high-risk populations, like MSM and intravenous drug users, often struggle with enrollment and retention due to stigma and fear of disclosure.

Solution: Collaborate with community organizations, ensure confidentiality, and provide culturally sensitive education to build trust and improve recruitment and retention.

7. Delayed Disease Progression in Trial Duration

Case Example: In trials assessing long-term efficacy (e.g., START trial), delayed disease progression made it challenging to observe treatment benefits within a short study period.

Solution: Extend follow-up periods in study designs or use surrogate endpoints, such as early changes in CD4 counts or viral load, to provide interim efficacy assessments.

Safety Concerns

1. Drug Toxicity and Long-term Side Effects:

- ART medications can cause a range of side effects, from mild to severe, depending on the drug class. Common side effects include gastrointestinal issues (nausea, diarrhea), fatigue, and headache. Long-term ART use can lead to more serious issues, such as kidney disease, liver toxicity, osteoporosis, and cardiovascular complications, particularly with older drug formulations like some nucleoside reverse transcriptase inhibitors (NRTIs). Newer drug classes, such as integrase inhibitors, generally have a better safety profile, but long-term data are still being collected.

2. Neuropsychiatric Effects:

- Certain ART drugs, notably non-nucleoside reverse transcriptase inhibitors (NNRTIs) like efavirenz, can cause neuropsychiatric side effects such as vivid dreams, mood changes, anxiety, and depression. These side effects may lead some patients to discontinue treatment, impacting adherence. As a result, alternative therapies are often considered, particularly for patients with a history of mental health issues.

3. Drug Resistance:

- HIV's high mutation rate can lead to the development of drug-resistant viral strains, particularly if adherence to ART is inconsistent. Drug resistance reduces treatment effectiveness, limits future therapeutic options, and requires switching to more complex, often more expensive drug regimens. To minimize resistance, patients are often closely monitored, and combination therapies are adjusted as needed.

4. Immune Reconstitution Inflammatory Syndrome (IRIS):

- IRIS is a paradoxical immune reaction that can occur in patients with advanced HIV who initiate ART. As the immune system begins to recover, it may respond aggressively to previously undetected infections, causing inflammation and symptoms that can be severe or even life-threatening. Management of IRIS involves both continuing ART and treating any underlying infections.

5. Cardiovascular and Metabolic Complications:

- HIV infection and long-term ART use can increase the risk of cardiovascular disease and metabolic disorders, including diabetes and dyslipidemia. This risk is influenced by chronic inflammation due to HIV, as well as side effects of certain ART drugs, particularly protease inhibitors. Managing these risks often involves lifestyle interventions, regular monitoring, and possible addition of medications to control cholesterol and blood sugar.

Standard of Care Treatment Options

1. Antiretroviral Therapy (ART):

- The standard ART regimen usually consists of a combination of at least three antiretroviral drugs from two or more classes, most commonly including an integrase inhibitor (e.g., bictegravir or dolutegravir) and two NRTIs (e.g., tenofovir and emtricitabine). These combination regimens reduce the risk of resistance and ensure robust viral suppression. Single-pill, fixed-dose combinations (e.g., Biktarvy, Triumeq) are preferred for their simplicity and high adherence rates.

2. Monitoring and Viral Load Testing:

- Regular monitoring is essential to ensure the effectiveness of ART and to detect any potential side effects early. Viral load testing is performed at initial diagnosis and periodically during treatment to confirm that the virus remains suppressed. CD4 count monitoring is also conducted, particularly in patients with advanced HIV, to track immune system recovery and assess the risk for opportunistic infections.

3. Pre-Exposure and Post-Exposure Prophylaxis (PrEP and PEP):

- PrEP, using drugs like Truvada or Descovy, is recommended for individuals at high risk of acquiring HIV. It provides significant protection against HIV when taken consistently. Post-exposure prophylaxis (PEP) is used in emergency situations following potential HIV exposure and involves a 28-day ART regimen initiated within 72 hours after exposure.

4. Management of Co-Morbidities and Preventive Care:

- Many HIV patients require additional care to manage co-morbid conditions such as cardiovascular disease, metabolic disorders, and hepatitis B or C co-infections. Preventive care, including vaccinations (e.g., hepatitis, influenza, pneumonia), routine screenings, and lifestyle counseling, are integral to the holistic management of HIV patients.

5. Patient Support and Adherence Programs:

- Given the importance of strict adherence to ART, comprehensive patient support programs are critical. These programs may include counseling, education on HIV and ART, and addressing barriers to adherence, such as mental health support and managing side effects. Mobile health applications, reminders, and community support groups also play a role in supporting adherence and improving patient outcomes.

Emerging Developments in HIV Standard of Care

Advances in HIV treatment are increasingly focused on simplifying regimens with long-acting injectables (e.g., cabotegravir and rilpivirine) that reduce the need for daily dosing, potentially improving adherence and quality of life. Research into HIV vaccines and functional cures, including gene therapies and broadly neutralizing antibodies, continues, with the aim of further reducing HIV incidence and enhancing patient outcomes.

INGENŪ CRO

Enhancing Clinical Trial Protocols for HIV/AIDS

Improving clinical trial protocols for HIV/AIDS is pivotal to advancing our understanding and treatment. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Adaptive Trial Designs:

Overview: Adaptive trial designs allow for modifications based on interim results, such as dose adjustments or altering the patient population. For HIV drugs, this can mean identifying the optimal dose for viral suppression or adjusting the trial to better assess efficacy in subgroups with particular needs, such as highly treatment-experienced patients.

Benefit: This flexibility can enhance the trial's efficiency and relevance, as adjustments based on early findings can optimize both efficacy and safety data, which the FDA may view positively.

2. Inclusion of Long-Acting Formulations:

Overview: Long-acting injectables are becoming a preferred alternative for patients who struggle with daily dosing. Including both oral and long-acting injectable forms in a single protocol can demonstrate the drug's versatility and address a broader range of patient needs.

Benefit: This approach aligns with the FDA's emphasis on practical, patient-centered treatments and could improve the drug's market appeal if approved, as it meets various adherence and lifestyle requirements.

3. Real-World Evidence (RWE) Collection:

Overview: Collecting real-world evidence (e.g., data from observational studies or patient registries) can supplement clinical trial data, particularly for safety, tolerability, and adherence in diverse populations.

Benefit: The FDA increasingly values RWE, especially for chronic conditions like HIV, as it provides additional insights into how the drug performs outside of the clinical trial setting. Including a real-world evidence component strengthens the application and could facilitate expanded approval.

4. Diverse Participant Recruitment:

Overview: Ensuring diversity in trial participants by including individuals from different racial, ethnic, gender, and age groups improves the generalizability of the findings. HIV disproportionately affects certain demographics, so data on how different populations respond to the drug is important for both the FDA and for meeting public health needs.

Benefit: Trials with diverse populations allow the FDA to assess drug safety and efficacy across varied demographics, potentially easing the path to broader approval and addressing disparities in HIV treatment.

5. Patient-Reported Outcome Measures (PROMs):

Overview: Including PROMs, such as surveys on quality of life, symptom burden, and treatment satisfaction, adds a patient-centric perspective to the data. This can be especially valuable in HIV, where long-term treatment adherence is closely tied to patient experience.

Benefit: The FDA has a strong interest in patient-focused drug development, and positive PROM data may support claims of improved adherence, tolerability, and quality of life, which can differentiate the drug in the approval process.

Notable Key Opinion Leaders in HIV/AIDS Research

Name	Specialty	Designation	Location	Brief Bio
Sharon R Lewin (FRACP, PhD, MBBS)	Allergy and Immunology; Infectious Disease	Professor, University of Melbourne	Victoria, Australia	Sharon R. Lewin is an internationally recognized researcher in HIV/AIDS and infectious diseases. She is the inaugural director of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. Known for her research on HIV latency and potential cures, she has been instrumental in advancing understanding of viral persistence in HIV, which is crucial for cure strategies. She has received numerous awards, including the Australian Academy of Health and Medical Sciences Fellowship and was named one of the Australian Financial Review's 100 Women of Influence.
Jennifer F Hoy (MBBS, FRACP)	Infectious Disease	Professor, Monash University	Victoria, Australia	Jennifer F. Hoy is a prominent figure in HIV research with a focus on clinical care and treatment for HIV-infected patients. She leads the HIV clinical research program at Monash University and Alfred Health. Her work has significantly contributed to the improvement of antiretroviral therapy and management of comorbidities in people living with HIV. Hoy has been recognized for her efforts in clinical research and her dedication to improving the health outcomes of individuals with HIV.
Gail V Matthews (MBBS, FRACP, PhD)	Infectious Disease	Professor, University of New South Wales	New South Wales, Australia	Gail Matthews is a clinical academic known for her research on HIV, particularly in the context of coinfections like hepatitis C. At UNSW, she has led multiple clinical trials and studies on HIV treatment and prevention. Matthews has also contributed extensively to policy and guidelines related to HIV management in Australia. She is recognized as a leading expert in the fields of HIV and hepatitis C, especially regarding antiviral treatments and public health impacts.
Dominic E Dwyer (MBBS, FRACP, FRCPA)	Infectious Disease; Microbiology	Clinical Professor, University of Sydney	New South Wales, Australia	Dominic Dwyer is a Clinical Professor in Infectious Diseases at the University of Sydney and serves as a director at NSW Health Pathology. He is highly regarded for his expertise in HIV virology and diagnostics, and he has contributed extensively to research in viral infections, including his work on HIV/AIDS and other emerging infectious diseases. Dwyer is well-known for his role in public health and infection control and is frequently consulted on virological issues within Australia. He has published widely and contributed to major public health guidelines.
David A Cooper (MD, PhD, FRACP, FRCPA)	Infectious Disease; Allergy and Immunology	Professor, University of New South Wales	New South Wales, Australia	David A. Cooper (deceased in 2018) was a leading HIV/AIDS researcher and the inaugural director of the Kirby Institute for Infection and Immunity in Society at UNSW Sydney. His pioneering work in HIV/AIDS spanned over three decades, during which he helped establish Australia as a leader in HIV research. Cooper's contributions included early recognition of HIV/AIDS and the development of antiretroviral therapies. He was instrumental in establishing multiple international collaborations to address HIV/AIDS in resource-limited settings, especially in Asia and the Pacific. He was awarded the prestigious Companion of the Order of Australia (AC) for his services to medicine.

References

- Centers for Disease Control and Prevention. (2022). HIV Treatment.
- Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., ... & HPTN 052 Study Team. (2016). Antiretroviral therapy for the prevention of HIV-1 transmission. New England Journal of Medicine, 375(9), 830-839.
- Department of Health and Human Services. (2023). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.
- Eisinger, R. W., Dieffenbach, C. W., & Fauci, A. S. (2019). HIV viral load and transmissibility of HIV infection: Undetectable equals untransmittable. JAMA, 321(5), 451-452.
- Joint United Nations Programme on HIV/AIDS (UNAIDS). (2023). Global HIV & AIDS statistics — Fact sheet.
- Saag, M. S., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Thompson, M. A., Sax, P. E., ... & Smith, D. M. (2020). Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel. JAMA, 324(16), 1651-1669.
- World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach.
- Zhang, W., Du, Y., Bai, J., & Cheng, G. (2022). Advances in HIV treatment and prevention: Potential of long-acting injectable antiretrovirals. Frontiers in Pharmacology, 13, 841135.
- Zhou, G., & Li, X. (2021). Antiretroviral therapy and HIV prevention: Challenges and prospects. Infectious Diseases of Poverty, 10(1), 1-10.
- Zoufaly, A., Cozzi-Lepri, A., Reekie, J., Kirk, O., Lundgren, J., Reiss, P., ... & EuroSIDA Study Group. (2019). Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV patients in Europe. HIV Medicine, 20(1), 99-109.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com